{
    "id": "wrong_mix_domainrange_subsidiary_00056_0",
    "rank": 87,
    "data": {
        "url": "https://spiden.com/team-old/",
        "read_more_link": "",
        "language": "en",
        "title": "old – SPIDEN",
        "top_image": "https://spiden.com/wp-content/uploads/2020/11/spiden_favicon-150x150.png",
        "meta_img": "https://spiden.com/wp-content/uploads/2020/11/spiden_favicon-150x150.png",
        "images": [
            "https://spiden.com/wp-content/uploads/2020/11/Hamburger-1.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Hamburger-1.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-30.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-30.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-30.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-30.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-30.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-30.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-34.svg",
            "https://spiden.com/wp-content/uploads/2020/11/Gruppe-34.svg",
            "https://spiden.com/wp-content/uploads/2020/11/spiden_navilogo.svg",
            "https://spiden.com/wp-content/uploads/2020/11/spiden_navilogo.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2023-10-29T19:20:50+00:00",
        "summary": "",
        "meta_description": "Team & Advisory Board OUR PEOPLE We built a team with deep experience in serial entrepreneurship, MedTech product development and Spiden’s key science disciplines. OUR TEAM Management Leo Grünstein Founder & CEO​ Founder of LG Capital, a Family Office focused on incubation of “big idea” ventures Serial entrepreneur, investor & Co-Founder of more than two […]",
        "meta_lang": "en",
        "meta_favicon": "https://spiden.com/wp-content/uploads/2020/11/spiden_favicon-150x150.png",
        "meta_site_name": "SPIDEN",
        "canonical_link": "https://spiden.com/team-old/",
        "text": "Serial VC & PE investor with multiple successful exits\n\nFormerly CEO of McKinsey Switzerland, and member of McKinsey’s Global Board, mostly focusing on financial services (Head of EMEA Banking)\n\nVarious Board positions in Switzerland incl. Lucernefestival, and Tafeln Schweiz\n\nPhD and M.Sc. in Business Administration from University of St. Gallen\n\nVenture Partner at New Enterprise Associates in Palo Alto since 2015; serving on several Boards (e.g., Baxter)\n\nFormerly Medtronic’s Senior Vice-President for Medicine and Technology and a member of the Medtronic Executive Committee for 14 years\n\nServed on the faculty at Stanford and Harvard Medical Schools while directing the Invasive Cardiology Services at Stanford Hospital and the Massachusetts General Hospital\n\nFormer Corporate President and Chief Strategy Officer of Samsung Electronics\n\nChairman of the Board of Harman International, served on the Boards of Arm, Cadence and Cymer\n\nSeed investor to companies such as Berkeley Lights, Fungible, Zoom Video, Graphcore and TTTech, continuous to be very active venture investor\n\nAuthor of the international bestseller “Glucose Revolution” (2022) and “The Glucose Goddess Method” (2023)\n\nFounder of Glucose Goddess, providing actionable advice based on cutting-edge science, focusing on the importance of balancing one’s blood sugar to maximize health and longevity, which has garnered a community of >2m followers\n\nFormerly Senior Product Manager at 23andMe, focusing on bridging genetic information and consumer behavior change\n\nPhysician executive with 30+ years of international experience in life sciences\n\nCurrently Chairman of Orsco Lifesciences, successfully selling/listing 9 companies, including a unicorn\n\nFormer Medtronic’s Senior Vice-President and President of EMEA, Canada & emerging markets for 12 years, founded the Structural Heart Division and launched the first commercially available percutaneous heart valve in the world\n\nBoard member of Boston Scientific and Board member at CVS health\n\nFormer Chairman of the Board of Becton, Dickinson and Company from 2002-2012, and its CEO from 2000-2011\n\nFormerly served as a Director of Xylem, and as Vice Chair of the Board of trustees of the Hackensack University Medical Center Network\n\nChair of Physical Chemistry at Friedrich Schiller University Jena\n\nScientific Director of the Liebniz Institute of Photonic Technology, Jena\n\nResearch interest includes biophotonics, in particular with the development and application of innovative Raman techniques for biomedical diagnosis\n\nPhD in Chemistry from University of Würzburg, Post-doc from Yale University\n\nProfessor of Intensive Care Medicine at University College London with over 30 years’ research experience\n\nHas developed and co-developed medical devices resulting in e.g., reduced length of stay after surgery, improved COVID-19 care\n\nCo-chaired the Sepsis-3 International Task Force that redefined sepsis (Singer JAMA 2016); paper has had >3 million views and is one of the most heavily cited in the scientific literature over the past 5 years\n\nManaging Director with Accenture focused on technology and digitization\n\nVP of the Board of Advance – women in business society\n\nFormerly Partner with McKinsey, where she worked for 17 years, focused on Pharma, Biotech & Technology\n\nPost-doc, PhD and MSc in Biology and Immunology at Ludwig-Maximilians University\n\nChief Physician of the Clinic for Cardiac Surgery in the City Hospital Triemli Zurich\n\nMore than 20 years’ of experience in cardiology\n\nFull Professor in the Faculty of Medicine, State University Tetova (Macedonia); Lecturer in Goethe-Universität Frankfurt am Main and University of Zurich\n\nDoctorate in Medicine from Johannes Gutenberg-Universität in Mainz\n\nFormer Executive VP, Clinical Research Services and Chief Medical Officer, Parexel\n\nInternational\n\nMore than 15 years experience consulting to early-stage and established companies in drug\n\nand medical device development\n\nInterventional cardiologist with over 20 years experience in academic and clinical medical\n\npractice, and designing and conducting clinical trials in cardiovascular drugs and devices\n\nProfessor of Biomedical Engineering and Materials Science and Engineering at Boston University with more than 20 years of experience in development of novel biomaterials\n\nResearch interests include theranostics (detection and treatment) for cardiovascular diseases and cancer; tissue-engineered and nanoparticle strategies for cardiovascular diseases\n\nPhD from Massachusetts Institute of Technology\n\nSerial healthcare and medical technology entrepreneur in Europe and the US with multiple successful exits in the dialysis and renal care sector\n\nAdjunct Professor of Imperial College Business School in London, Mentor at Imperial Enterprise Lab’s Venture Mentoring Service as well as a member of the Chair of Entrepreneurship at ETH Zurich. Jury member of Venture Kick, Switzerland’s largest startup accelerator program\n\nProfessor of Medicine, Pediatrics, Biophysics and Robert Linday Chair of Dialysis Research and Innovation at the University of Western Ontario, London\n\nLeading a team of multidisciplinary researchers focused largely on the pathophysiology of the effecting cardiovascular, brain, liver and gastro-intestinal structure and function in patients with chronic kidney disease\n\n3 years as Assistant Professor in Neurophysiology at Düsseldorf University and 14 years at the Clinic for Nutrition and Metabolism\n\nFounder and CEO of the Profil Institut für Stoffwechselforschung in Neuss, Germany until 2009; member of multiple diabetes associations, Scientific Advisory Boards for pharmaceutical companies, and Managing Editor of the Journal of Diabetes Science and Technology\n\nResearch focuses on insulin pharmacology and diabetes technology; coordinated EU-funded project AP@home from 2010 to 2015"
    }
}